Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.

@article{Wood2017DualAA,
  title={Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.},
  author={Andrew Craig Wood and Kateryna V. Krytska and Hannah T. Ryles and Nicole R. Infarinato and Renata Sano and Theodore D. Hansel and Lori S. Hart and Frederick J. King and Timothy Richard Smith and Edward K Ainscow and Kathryn Brooke Grandinetti and Tove Tuntland and Sunkyu Kim and Giordano Michael. Caponigro and You Qun He and Shiva Krupa and Nanxin Li and Jennifer Lynn Harris and Ya{\"e}l P. Moss{\'e}},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2017},
  volume={23 11},
  pages={
          2856-2868
        }
}
Purpose: Anaplastic lymphoma kinase (ALK) is the most frequently mutated oncogene in the pediatric cancer neuroblastoma. We performed an in vitro screen for synergistic drug combinations that target neuroblastomas with mutations in ALK to determine whether drug combinations could enhance antitumor efficacy.Experimental Design: We screened combinations of eight molecularly targeted agents against 17 comprehensively characterized human neuroblastoma-derived cell lines. We investigated the… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Molecularly Targeted Therapy for Neuroblastoma

  • Children
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 44 REFERENCES

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2013
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2016
VIEW 1 EXCERPT